Table 2.

Epigenetic drugs in clinical trials

Class	Drug	Treatment method	Cancer type	Current status	Clinical trial	Reference/identifier
DNMTi	Azacitidine	Only	MDS, CMML	Completed	FDA approved	[279]
		Only	AML	Completed	Phase III	NCT01074047
		+ Pembrolizumab	Pancreas cancer	Recruiting	Phase II	NCT03264404
		+ Valproic acid	Advanced cancer	Completed	Phase I	NCT00496444
		+ Quizartinib	Recurrent AML, CMML and MDS	Active, not recruiting	Phase I/ II	NCT01892371
	Decitabine	Only	MDS, CMML	Completed	FDA approved	[280]
		Only	AML	Completed	Phase III	NCT00260832
		+ Fludarabine and busulfan	AML, MDS	Completed	Phase 1	NCT01455506
		+ Quizartinib + venetoclax	Recurrent AML and MDS	Recruiting	Phase I/ II	NCT03661307
	Guadecitabine	Only	AML	Completed	Phase 2	NCT01261312
		Only	HCC	Completed	Phase 2	NCT01752933
		+ Pembrolizumab + mocetinostat	Lung cancer	Recruiting	Phase 1	NCT03220477
	Disulfiram	Only	Metastatic breast cancer	Recruiting	Phase II	NCT03323346
		Only	Prostat cancer	Completed	Not applicable	NCT01118741
HDACi	Romidepsin	Only	CTCL	Completed	FDA approved	[281]
		+ Erlotinib	Stage III/ IV NSCLC	Completed	Phase I	NCT01302808
HDACi	Panobinostat (LBH-589)	+ Bortezomib and dexamethasone	Myeloma who received at least bortezomib and IMiDs	Completed	FDA approved	[282]
		Only	Prostat cancer	Completed	Phase I	NCT00663832
		Only	Colorectal cancer	Completed	Phase II	NCT00690677
	Vorinostat (SAHA)	Only	CTCL	Completed	FDA approved	[283]
		Only	AML	Completed	Phase 2 trial	NCT00305773
		+ Radiation therapy	AML Pancreatic cancer	Terminated	Phase I/II	NCT00831493
		+ Carboplatin + etoposide	SCLC	Terminated	Phase I/II	NCT00702962
		Only	NSCLC	Completed	Phase I	NCT01059552
		Only	Glioblastoma stem cells	Completed	Phase II	[284]
	Chidamide	Only	PTCL	Completed	FDA approved	[285]
		+ Exemestane + placebo	Breast cancer	Active, not recruiting	Phase III	NCT02482753
		+ Paclitaxel + carboplatin + placebo	NSCLC	Completed	Phase II	NCT01836679
	Givinostat (ITF2357)	Only	Lung CSCs	Completed	Phase II	[284]
		Only	Chronic myeloproliferative neoplasms	Active, not recruiting	Phase II	NCT01761968
	Belinostat	Only	PTCL	Completed	FDA approved	[286]
		Only	Advanced cancer	Completed	Phase I	NCT01583777
		+ Ribociclib	Metastatic breast cancer, recurrent ovarian carcinoma	Recruiting	Phase I	NCT04315233
HDMi	Tranylcypromine	+ Tretinoin	AML, MDS, Leukemia	Completed	Phase I	NCT02273102
		+ All-trans retinoic acid + cytarabin	AML, MDS	Recruiting	Phase I/ II	NCT02717884
	Tazemetostat	Only	Malignant mesothelioma	Completed	Phase II	NCT02860286
		Only	Rhabdoid tumors, NI1-negative tumors, synovial sarcoma malignant, rhabdoid tumors of ovary	Recruiting	Phase I	NCT02601937
	CPI-1205	+ Ipilimumab	Advansed solid tumors	Completed	Phase I	NCT03525795
		Only	B cell lymphoma	Completed	Phase I	NCT02395601
ncRNA	EnGeneIC (mir-16 mimic)	Mitoxantrone packaged EDV (EnGeneIC delivery vehicle)	Solid tumors, CNS tumors	Recruiting	Phase I	NCT02687386
	MRX34 (mir-34a mimic)	Only	Primary liver cancer, SCLC, NSCLC, lymphoma, melanoma	Terminated	Phase I	NCT01829971
	TargomiRs	Only	MPM, NSCLC	Completed	Phase I	NCT02369198
	Patisiran	Only	hereditary transthyretin amyloidosis	Completed	FDA approved	[287]
	Cobomarsen (anti-mir155)	Only	CTCL, CLL, ATLL	Completed	Phase I	NCT02580552
		+ Vorinostat	Cutaneous T cell lymphoma/mycosis fungoides	Terminated	Phase II	NCT03713320